IDRSF Idorsia Ltd

USD 2.64 0.00 0
Icon

Idorsia Ltd (IDRSF) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.64

0.00 (0.00)%

USD 0.44B

N/A

N/A

N/A

Icon

IDRSF

Idorsia Ltd (USD)
COMMON STOCK | OTC
USD 2.64
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.44B

N/A

USD 2.64

Idorsia Ltd (IDRSF) Stock Forecast

N/A

Based on the Idorsia Ltd stock forecast from 0 analysts, the average analyst target price for Idorsia Ltd is not available over the next 12 months. Idorsia Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Idorsia Ltd is Bearish, which is based on 2 positive signals and 8 negative signals. At the last closing, Idorsia Ltd’s stock price was USD 2.64. Idorsia Ltd’s stock price has changed by +32.66% over the past week, +60.00% over the past month and -76.11% over the last year.

No recent analyst target price found for Idorsia Ltd
No recent average analyst rating found for Idorsia Ltd

Company Overview Idorsia Ltd

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunol...Read More

https://www.idorsia.com

Hegenheimermattweg 91, Allschwil, Switzerland, 4123

0

December

USD

USA

Adjusted Closing Price for Idorsia Ltd (IDRSF)

Loading...

Unadjusted Closing Price for Idorsia Ltd (IDRSF)

Loading...

Share Trading Volume for Idorsia Ltd Shares

Loading...

Compare Performance of Idorsia Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for IDRSF

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Idorsia Ltd (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S -0.95 (-0.75%) USD599.92B 48.04 5.17

ETFs Containing IDRSF

Symbol Name IDRSF's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Idorsia Ltd (IDRSF) Stock

Stock Target Advisor's fundamental analysis for Idorsia Ltd's stock is Bearish.

Unfortunately we do not have enough data on IDRSF's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on IDRSF's stock to indicate what its average analyst target is.

IDRSF stock's Price/Earning ratio is 130.60. Our analysis grades IDRSF stock's Price / Earning ratio at F. This means that IDRSF stock's Price/Earning ratio is above 89% of the stocks in the Biotechnology sector in the OTC exchange. Based on this IDRSF may be a overvalued for its sector.

The last closing price of IDRSF's stock was USD 2.64.

The most recent market capitalization for IDRSF is USD 0.44B.

Unfortunately we do not have enough analyst data on IDRSF's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Idorsia Ltd's stock.

As per our most recent records Idorsia Ltd has 0 Employees.

Idorsia Ltd's registered address is Hegenheimermattweg 91, Allschwil, Switzerland, 4123. You can get more information about it from Idorsia Ltd's website at https://www.idorsia.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...